



ABN 53 075 582 740

## ASX ANNOUNCEMENT

17 October 2022

---

### Filing of Form 20-F with the SEC

Bionomics Limited (ASX: BNO, NASDAQ: BNOX), (**Bionomics** or **Company**), a clinical stage biopharmaceutical company, today announced that it has filed its 2022 U.S. Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (**SEC**) for the financial year ended 30 June 2022 as required by the Company as a “foreign private issuer” in the U.S.

The Form 20-F has been prepared in accordance with the requirements of the SEC specifically for distribution in the U.S. and, as such, its presentation differs in some respects from the 2022 Bionomics Annual Report lodged with the Australian Securities Exchange (**ASX**) on 6 October 2022.

The Company’s American Depositary Shares (**ADSs**) are quoted on the NASDAQ Global Market at a ratio of 180 ordinary shares to one ADS, trading under the ticker code “BNOX”.

A copy of the Form 20-F can be found at <https://www.sec.gov/edgar/browse/?CIK=1191070&owner=exclude>.

Released on authority of the Executive Chairman.

#### FOR FURTHER INFORMATION PLEASE CONTACT:

**General:**

Ms. Suzanne Irwin  
Company Secretary  
+61 8 8150 7400  
[CoSec@bionomics.com.au](mailto:CoSec@bionomics.com.au)

**Investor Relations:**

Mr. Connor Bernstein  
Vice President, Strategy and Corporate Development  
+1 (650) 524-5143  
[cbernstein@bionomics.com.au](mailto:cbernstein@bionomics.com.au)

#### About Bionomics Limited

Bionomics (ASX:BNO, NASDAQ: BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the  $\alpha 7$  nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

[www.bionomics.com.au](http://www.bionomics.com.au)